FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154920207> ?p ?o ?g. }

• W3154920207 endingPage "2152" @default.
• W3154920207 startingPage "2142" @default.
• W3154920207 abstract "Despite central nervous system (CNS) relapse occurring in >10% of high-risk diffuse large B-cell lymphoma (DLBCL) patients, the role of CNS-directed prophylaxis is controversial in the absence of randomized controlled trials. In this retrospective study, we aimed to evaluate the safety and efficacy of prophylactic high-dose methotrexate (HD-MTX) on CNS relapse and survival outcomes in 258 newly diagnosed R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)-treated high-risk DLBCL patients, based on the initial treatment intent (ITT) of the physician on the use of prophylactic HD-MTX. Patients were classified into an ITT HD-MTX group (n = 128) and a non-ITT HD-MTX group (n = 130). The CNS relapse rate was not significantly different between these groups, with 2-year CNS relapse rates of 12.4% and 13.9%, respectively (P = 0.96). Three-year progression-free survival and overall survival rates in the ITT HD-MTX and non-ITT HD-MTX groups were 62.4% vs 64.5% (P = 0.94) and 71.7% vs 71.4% (P = 0.7), respectively. Also, propensity score-matched analyses showed no significant differences in the time-to-CNS-relapse, progression-free survival, or overall survival. The ITT HD-MTX group showed a higher incidence of grade ≥ 3 oral mucositis and elevated alanine aminotransferase. Prophylactic HD-MTX does not improve CNS relapse rate or survival outcomes in high-risk DLBCL patients, and it is accompanied by increased toxicities." @default.
• W3154920207 created "2021-04-26" @default.
• W3154920207 creator A5002062627 @default.
• W3154920207 creator A5004673227 @default.
• W3154920207 creator A5007506402 @default.
• W3154920207 creator A5022379369 @default.
• W3154920207 creator A5044958787 @default.
• W3154920207 creator A5049407736 @default.
• W3154920207 creator A5049646227 @default.
• W3154920207 creator A5054517073 @default.
• W3154920207 creator A5070374265 @default.
• W3154920207 creator A5075714089 @default.
• W3154920207 creator A5077797186 @default.
• W3154920207 creator A5084862748 @default.
• W3154920207 creator A5089384315 @default.
• W3154920207 creator A5089689144 @default.
• W3154920207 creator A5090031301 @default.
• W3154920207 date "2021-04-21" @default.
• W3154920207 modified "2023-10-18" @default.
• W3154920207 title "Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis" @default.
• W3154920207 cites W1982274007 @default.
• W3154920207 cites W1995939575 @default.
• W3154920207 cites W2004156230 @default.
• W3154920207 cites W2027668298 @default.
• W3154920207 cites W2028850684 @default.
• W3154920207 cites W2043622833 @default.
• W3154920207 cites W2058015212 @default.
• W3154920207 cites W2081568737 @default.
• W3154920207 cites W2089242301 @default.
• W3154920207 cites W2100367991 @default.
• W3154920207 cites W2110520204 @default.
• W3154920207 cites W2111322227 @default.
• W3154920207 cites W2119147717 @default.
• W3154920207 cites W2123971450 @default.
• W3154920207 cites W2126779872 @default.
• W3154920207 cites W2137581187 @default.
• W3154920207 cites W2142991507 @default.
• W3154920207 cites W2147686446 @default.
• W3154920207 cites W2154868392 @default.
• W3154920207 cites W2280269954 @default.
• W3154920207 cites W2462981464 @default.
• W3154920207 cites W2493103431 @default.
• W3154920207 cites W2518731208 @default.
• W3154920207 cites W2527922773 @default.
• W3154920207 cites W2531432151 @default.
• W3154920207 cites W2598700764 @default.
• W3154920207 cites W2742627598 @default.
• W3154920207 cites W2895788492 @default.
• W3154920207 cites W2905980862 @default.
• W3154920207 cites W2914421858 @default.
• W3154920207 cites W2944839297 @default.
• W3154920207 cites W3023631491 @default.
• W3154920207 cites W3047069860 @default.
• W3154920207 cites W3047361396 @default.
• W3154920207 cites W3096300067 @default.
• W3154920207 doi "https://doi.org/10.1182/bloodadvances.2020003947" @default.
• W3154920207 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8095148" @default.
• W3154920207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33881464" @default.
• W3154920207 hasPublicationYear "2021" @default.
• W3154920207 type Work @default.
• W3154920207 sameAs 3154920207 @default.
• W3154920207 citedByCount "18" @default.
• W3154920207 countsByYear W31549202072021 @default.
• W3154920207 countsByYear W31549202072022 @default.
• W3154920207 countsByYear W31549202072023 @default.
• W3154920207 crossrefType "journal-article" @default.
• W3154920207 hasAuthorship W3154920207A5002062627 @default.
• W3154920207 hasAuthorship W3154920207A5004673227 @default.
• W3154920207 hasAuthorship W3154920207A5007506402 @default.
• W3154920207 hasAuthorship W3154920207A5022379369 @default.
• W3154920207 hasAuthorship W3154920207A5044958787 @default.
• W3154920207 hasAuthorship W3154920207A5049407736 @default.
• W3154920207 hasAuthorship W3154920207A5049646227 @default.
• W3154920207 hasAuthorship W3154920207A5054517073 @default.
• W3154920207 hasAuthorship W3154920207A5070374265 @default.
• W3154920207 hasAuthorship W3154920207A5075714089 @default.
• W3154920207 hasAuthorship W3154920207A5077797186 @default.
• W3154920207 hasAuthorship W3154920207A5084862748 @default.
• W3154920207 hasAuthorship W3154920207A5089384315 @default.
• W3154920207 hasAuthorship W3154920207A5089689144 @default.
• W3154920207 hasAuthorship W3154920207A5090031301 @default.
• W3154920207 hasBestOaLocation W31549202071 @default.
• W3154920207 hasConcept C126322002 @default.
• W3154920207 hasConcept C141071460 @default.
• W3154920207 hasConcept C143998085 @default.
• W3154920207 hasConcept C2776694085 @default.
• W3154920207 hasConcept C2776755627 @default.
• W3154920207 hasConcept C2778496288 @default.
• W3154920207 hasConcept C2778720950 @default.
• W3154920207 hasConcept C2779338263 @default.
• W3154920207 hasConcept C2779429289 @default.
• W3154920207 hasConcept C2780653079 @default.
• W3154920207 hasConcept C2781059491 @default.
• W3154920207 hasConcept C2781214270 @default.
• W3154920207 hasConcept C71924100 @default.
• W3154920207 hasConcept C90924648 @default.
• W3154920207 hasConceptScore W3154920207C126322002 @default.
• W3154920207 hasConceptScore W3154920207C141071460 @default.

• next